No Data
No Data
QuidelOrtho to Participate in the 46th Annual Raymond James Institutional Investor Conference
$30+ Bn Primary Care POC Diagnostics Market Opportunities and Strategies to 2033: F. Hoffmann-La Roche Leads With 10.51% Share, Followed by Siemens Healthineers and QuidelOrtho
QuidelOrtho Full Year 2024 Earnings: EPS Misses Expectations
QuidelOrtho's Earnings Call: Mixed Sentiment Amidst Revenue Decline
QuidelOrtho Is Maintained at Outperform by RBC Capital
Raymond James Maintains QuidelOrtho(QDEL.US) With Buy Rating, Cuts Target Price to $60